Welcome to NRG Oncology!

Welcome to the NRG Oncology Web site! This resource serves to provide current information about NRG Oncology’s exciting research future and the latest updates about plans to support our clinical trial endeavors. We invite you to check back often to learn “what’s new.”

Who We Are

NRG Oncology brings together the unique and complementary research areas of the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG). NRG Oncology builds upon our more than 150 years of cumulative research experience to conduct practice defining, multi-institutional clinical trials resulting in the improved survival and quality of life of patients with cancer. NRG Oncology has been awarded a grant by the National Cancer Institute (NCI) as a member of the NCI National Clinical Trials Network (NCTN).

Click here to access all weekly broadcasts

NCORP Badge English636404806468909532

NRG Oncology is proud to be an 
active participant of Cancer Moonshot.




Learn about the leaders and plans for NRG Oncology's NCORP Research Base.


NRG Oncology
Four Penn Center, 1600 JFK Blvd, Suite 1020, Philadelphia, PA 19103
Contact Us

To receive the NRG Oncology Newsletter and occasional eNews announcements and press releases, please email

What’s New

NRG Oncology Surgical Oncology Committee now accepting applications. All materials due by March 2, 2018. Read more

NRG Oncology Appoints NCORP Investigator, Matthew Hudson, as Cancer Care Delivery Research  Committee Co-Chair Read more

Aghajanian Appointed as NRG Oncology Gynecologic Cancer Committee Chair Read more

Press Release Issued Regarding NRG Oncology's New Executive Director, Kati Stoermer Read more

NRG Oncology welcomes new Executive Director Read more

NRG Oncology Newsletter Volume 1, 2018 is now available! Read more

Trastuzumab does not negatively impact cardiac function for women with breast cancer in long-term follow-up Read more

New threat for those who publish: PREDATORY JOURNALS.  Read about this evolving issue under "Publications: Publication Updates" Read more

Antiangiogenesis Therapy Improves Overall Survival for Patients with Advanced Cervical Carcinoma Read more

Knowledge-Based Planning Model Aids Clinical Trial Outcomes Read more

MGMT Promoter Predicts Overall Survival for Patients with Anaplastic Astrocytoma Read more

Phase III trial confirms pelvic radiation as standard of care for high-risk, early-stage endometrial cancer Read more

Nomograms Developed and Validated for Patients with Squamous Cell Carcinoma of Larynx by NRG Oncology Read more

Results of NRG Oncology SBRT Comparison Trial for Lung Cancer Patients Consistent after Long-term Follow-up Read more

First Study of Its Kind Depicts Benefits of Brachytherapy for Patients with recurrent Prostate Cancer after EBRT Read more

Results Robert S. Mannel, MD Appointed as an NRG Oncology Group Chairman. Read more

NRG Oncology Newsletter Volume 4 2017 is now available! Read more

The NRG Oncology Biobank locations at the MD Anderson Cancer Center and Baylor University in Houston are now operational and able to receive USPS and express mail shipments. Effective immediately, please resume normal shipping procedures according to protocol requirements.

Results of secondary analysis of NRG Oncology/NSABP B-30 associates taxane use with long-term PN for breast cancer patients. Read more

NRG Oncology Hurricane Harvey Update Read more

Nomograms Provide Accurate Prediction of Overal Survival and Progression-Free Survival for Patients with Oropharyngeal Cancer. Read more

Results of NRG-RTOG 0436 Highlight Need for Biomarkers in Treatment of Esophageal Cancer. Read more

Ixazomib and Pevonedistat Project Team Member application available; due July 30, 2017. Read more

NRG Oncology Newsletter Volume 3 2017 is now available. Read more

Copyright 2018 by NRG Oncology